• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Re: Roberto Contieri, Patrick J. Hensley, Wei Shen Tan, et al. Oncological Outcomes for Patients with European Association of Urology Very High-risk Non-muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guérin or Early Radical Cystectomy. Eur Urol Oncol. 2023;6:590-596.

作者信息

Montorsi Francesco, Rosiello Giuseppe, Gandaglia Giorgio

机构信息

Unit of Urology, Division of Experimental Oncology, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy.

Unit of Urology, Division of Experimental Oncology, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy.

出版信息

Eur Urol Oncol. 2024 Apr;7(2):300. doi: 10.1016/j.euo.2023.09.016. Epub 2023 Oct 12.

DOI:10.1016/j.euo.2023.09.016
PMID:37838554
Abstract
摘要

相似文献

1
Re: Roberto Contieri, Patrick J. Hensley, Wei Shen Tan, et al. Oncological Outcomes for Patients with European Association of Urology Very High-risk Non-muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guérin or Early Radical Cystectomy. Eur Urol Oncol. 2023;6:590-596.回复：罗伯托·孔蒂耶里、帕特里克·J·亨斯利、魏申·谭等。卡介苗或早期根治性膀胱切除术治疗欧洲泌尿外科学会极高危非肌层浸润性膀胱癌患者的肿瘤学结局。《欧洲泌尿外科肿瘤学》。2023年；6：590 - 596。
Eur Urol Oncol. 2024 Apr;7(2):300. doi: 10.1016/j.euo.2023.09.016. Epub 2023 Oct 12.
2
Reply to Francesco Montorsi, Giuseppe Rosiello, and Giorgio Gandaglia's Letter to the Editor re: Roberto Contieri, Patrick J. Hensley, Wei Shen Tan, et al. Oncological Outcomes for Patients with European Association of Urology Very High-risk Non-muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guérin or Early Radical Cystectomy. Eur Urol Oncol. 2023;6:590-596.对弗朗切斯科·蒙托西、朱塞佩·罗西耶洛和乔治·甘达利亚致编辑的信的回复，信的主题为：罗伯托·孔蒂耶里、帕特里克·J·亨斯利、魏申·谭等人。欧洲泌尿外科协会极高危非肌层浸润性膀胱癌患者接受卡介苗或早期根治性膀胱切除术的肿瘤学结局。《欧洲泌尿外科肿瘤学》。2023年；6：590 - 596。
Eur Urol Oncol. 2024 Apr;7(2):301. doi: 10.1016/j.euo.2023.09.018. Epub 2023 Oct 6.
3
Oncological Outcomes for Patients with European Association of Urology Very High-risk Non-muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guérin or Early Radical Cystectomy.欧洲泌尿外科学会极高危非肌肉浸润性膀胱癌患者行卡介苗或早期根治性膀胱切除术的肿瘤学结局。
Eur Urol Oncol. 2023 Dec;6(6):590-596. doi: 10.1016/j.euo.2023.07.012. Epub 2023 Aug 8.
4
Re: Wei Shen Tan, Ian M. McElree, Facundo Davaro, et al. Sequential Intravesical Gemcitabine and Docetaxel Is an Alternative to Bacillus Calmette-Guérin for the Treatment of Intermediate-risk Non-muscle-invasive Bladder Cancer. Eur Urol Oncol. 2023;6:531-534.回复：沈伟、伊恩·M·麦克尔里、法昆多·达瓦罗等人。序贯膀胱内注射吉西他滨和多西他赛是卡介苗治疗中危非肌层浸润性膀胱癌的替代方案。《欧洲泌尿外科肿瘤学杂志》。2023年；6：531 - 534。
Eur Urol Oncol. 2024 Feb;7(1):163. doi: 10.1016/j.euo.2023.08.007. Epub 2023 Sep 9.
5
Evaluating the cost-utility of intravesical Bacillus Calmette-Guérin versus radical cystectomy in patients with high-risk non-muscle-invasive bladder cancer in the UK.评估卡介苗膀胱灌注与根治性膀胱切除术对英国高危非肌层浸润性膀胱癌患者的成本效益。
J Med Econ. 2023 Jan-Dec;26(1):411-421. doi: 10.1080/13696998.2023.2189860.
6
Prognostication in Japanese patients with bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer undergoing early radical cystectomy.日本接受早期根治性膀胱切除术的卡介苗无反应性非肌肉浸润性膀胱癌患者的预后预测。
Int J Urol. 2022 Mar;29(3):242-249. doi: 10.1111/iju.14759. Epub 2021 Dec 13.
7
Re: Francesco Soria, Matteo Rosazza, Simone Livoti, et al. Repeat Transurethral Resection (TUR) + Bacillus Calmette-Guérin (BCG) Versus Upfront Induction BCG After TUR in High-risk Non-muscle-invasive Bladder Cancer: Feasibility Phase of a Randomized Controlled Study. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2023.10.019.回复：弗朗切斯科·索里亚、马泰奥·罗萨扎、西蒙娜·利沃蒂等人。高危非肌层浸润性膀胱癌经尿道重复电切术（TUR）联合卡介苗（BCG）与TUR术后先行诱导性BCG治疗的比较：一项随机对照研究的可行性阶段。《欧洲泌尿外科聚焦》。即将发表。https://doi.org/10.1016/j.euf.2023.10.019
Eur Urol Focus. 2024 Mar;10(2):246. doi: 10.1016/j.euf.2023.12.007. Epub 2024 Jan 24.
8
European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ).欧洲泌尿外科学会非肌层浸润性膀胱癌（Ta、T1和原位癌）指南
Eur Urol. 2022 Jan;81(1):75-94. doi: 10.1016/j.eururo.2021.08.010. Epub 2021 Sep 10.
9
Patterns of recurrence and outcomes following induction bacillus Calmette-Guerin for high risk Ta, T1 bladder cancer.高危Ta、T1期膀胱癌诱导使用卡介苗后的复发模式及预后
J Urol. 2007 May;177(5):1727-31. doi: 10.1016/j.juro.2007.01.031.
10
Construction of predictive models for cancer-specific survival of patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: results from a multicenter retrospective study.卡介苗治疗非肌层浸润性膀胱癌患者癌症特异性生存预测模型的构建：一项多中心回顾性研究结果
Jpn J Clin Oncol. 2014 Nov;44(11):1101-8. doi: 10.1093/jjco/hyu119. Epub 2014 Aug 19.